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EXTRACELLULAR RNAS AS POTENTIAL BIOMARKERS FOR PLACENTAL 
DYSFUNCTION 
TREVOR R. LEONARDO 
ABSTRACT 
 Placental dysfunction affects approximately 1 in 10 pregnant women in both the 
developed and developing worlds. Most commonly, it is manifested as preeclampsia or 
fetal growth restriction. Over the past two decades, an increasing body of research into 
the developmental biology of the placenta has been amassed, which points to defects in 
the differentiation of the trophoblast cell lineage as a key player in the pathophysiology 
of placental dysfunction. A number of clinical parameters are known to be associated 
with an elevated risk of placental dysfunction. These include maternal risk factors (such 
as chronic hypertension, renal disease, and lupus), history of placental dysfunction in a 
prior pregnancy, abnormalities in the levels of certain proteins in the maternal blood that 
are commonly used to estimate the risk of fetal genetic defects, and abnormalities in 
uterine artery Doppler waveforms. These current methods have significant drawbacks, 
including low specificity and sensitivity, high cost, lack of widespread availability, and 
lack of validity early in pregnancy. In order to provide a more cost-effective and reliable 
method to detect an elevated risk for placental dysfunction early in pregnancy, we 
explored the potential for extracellular RNAs (exRNA) in the maternal serum to be used 
as biomarkers. In our study, we used next generation sequencing technologies to compare 
extracellular microRNA (miRNA) levels in serum samples of pregnant women of 
different gestational ages, nonpregnant women, and placental tissue samples. We 
	  	   v 
discovered that the large majority of microRNAs that were present at higher levels in 
pregnant serum samples than nonpregnant serum samples and were likely of placental 
origin. We also found that these pregnancy-specific miRNAs were enriched for miRNAs 
encoded on chromosomes (Chr) 14 and 19, with changes in the relative expression of 
these two groups of miRNAs throughout pregnancy. Moreover, the miRNA signatures of 
late gestational pregnant samples correlated more closely with placental tissue samples 
than those of early pregnant samples, which could be related to the increasing impact of a 
larger placenta on the maternal serum exRNA profile. Our results demonstrate the 
potential utility of next generation sequencing technologies in regards to differentiating 
between different conditions using clinical samples.     
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INTRODUCTION 
 
 Every person on this planet has implanted their blastocyst-stage-self into the 
endometrial lining of their mother’s uterus, and a subset of the trophoblast cells in their 
placenta has invaded deep into the uterine wall in order to gain access to crucial nutrients, 
water, and oxygen to grow and develop. For most people, this process happens smoothly 
and development continues normally. However, when implantation and invasion of the 
uterus go awry, many problems arise that can be detrimental to the health of both the 
mother and the developing fetus. Placental dysfunction, also known as placental 
insufficiency, is a complication that occurs when the placenta cannot provide adequate 
support to exchange nutrients and waste products between the fetus and the mother 
(Benirschke, Kaufmann, & Baergen, 2006). Placental dysfunction can result in a 
constellation of pregnancy complications, including preeclampsia, intrauterine growth 
restriction, and placental abruption. While the precise mechanisms leading to placental 
dysfunction are not entirely clear, there are a few commonly accepted ideas regarding the 
general causes of this condition during development. Furthermore, there are specific risk 
factors that are used clinically to identify patients at elevated risk for developing 
placental dysfunction, as well as specific criteria for diagnosis of its various 
manifestations. 
Clinical Aspect of Placental Dysfunction and Related Complications 
 In 2007, 16.7, 6.1, and 3.9 percent of infant deaths were caused by complications 
related to low birthweight, newborns affected by maternal complications of pregnancy, 
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and by abnormalities of the placenta, cord, and membranes, respectively (Xu, Kochanek, 
Murphy, & Tejada-Vera, 2010). Placental dysfunction is typically defined as an inability 
of the placenta to supply a sufficient amount of nutrients and oxygen to the fetus, making 
it unable to provide full support to the developing baby. This can occur due to mechanical 
problems with the placenta or umbilical cord, improper development of the placenta in 
early-mid pregnancy leading to small placental size, or other pregnancy complications. 
Many clinical studies have been conducted in an attempt to characterize the incidence 
and severity of placental dysfunction and related complications, which have led to the 
present tools used for diagnosis and management of these complications. Maternal risk 
factors for placental dysfunction include diabetes, hypertension, conditions that increase 
blood clotting risk, smoking, drug use, and certain medications (“A.D.A.M. Medical 
Encyclopedia,” 2014). There is also an association with an increased risk for placental 
dysfunction if the patient has a history of two or more miscarriages prior to the current 
pregnancy (Gunnarsdottir, Stephansson, Cnattingius, Åkerud, & Wikström, 2014). In a 
study observing neonates that were diagnosed with fetal growth restriction due to 
placental dysfunction, gestational age was the major determining factor in survival, 
where reaching a higher gestational age before birth significantly improved the rate of 
survival of the neonate (Baschat et al., 2007).  
 Intrauterine growth restriction is a term used to define a fetus with an estimated 
weight that is below the 3rd percentile when compared to all fetuses at the same 
gestational age and is typically the result of a problem during development of the fetus 
and/or the placenta (Table 1) (Lausman, McCarthy, & Walker, 2012). Intrauterine growth 
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restriction has been shown to increase the morbidity and mortality of premature neonates 
between gestational ages of 25-32 weeks, including an increased risk of necrotizing 
enterocolitis and need for prolonged respiratory support (Bernstein, Horbar, Badger, 
Ohlsson, & Golan, 2000; Garite, Clark, & Thorp, 2004). There has also been an 
association with an increasing risk of spontaneous preterm birth if the fetus has a low 
estimated weight for its gestational age (Lackman, Capewell, Richardson, daSilva, & 
Gagnon, 2001). Intrauterine growth restriction is thought to be more closely associated 
with placental dysfunction, compared to small for gestational age fetuses (between the 3rd 
and 10th percentiles for growth), which is more likely to be caused by factors such as the 
genetic contributions of the parents. 
Table 1. Fetal Weight Classification. Fetuses are placed in specific categories based on 
their weight for their gestational age. This reference is commonly used in the clinic to 
help clinicians determine whether or not further action should be taken when considering 
potential complications due to a small or larger than normal fetus. 
Fetal Weight for Gestational Age Term used to describe the Condition 
< 3rd percentile Intrauterine Growth Restriction 
< 10th percentile Small for Gestational Age 
11-89th percentile Normal 
>90th percentile Large for Gestational Age 
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 Preeclampsia is a pregnancy complication clinically diagnosed by the presence of 
both pregnancy-specific hypertension (maternal blood pressure that is ≥140 mm Hg 
systolic or ≥90 mm Hg diastolic in a woman who was normotensive prior to pregnancy), 
and proteinuria (≥0.3 grams of protein in a 24 hour urine collection) (Sibai, 2003). It is 
possible that preeclampsia arises from two distinct origins: reduced placental perfusion 
due to a placental pathology, and preexisting maternal disorders including hypertension, 
renal disease, being overweight, and diabetes (Ness & Roberts, 1996). It is estimated that 
preeclampsia affects 6-8% of all pregnancies, and is a factor in many cases of decreased 
birth weight (most significantly for preterm births) when compared to normotensive 
pregnancies (Xiong, Demianczuk, Saunders, Wang, & Fraser, 2002). A population-based 
study done in Norway looking at preeclamptic pregnancies over the past 35 years showed 
a nearly 20% increase in induced births from 1991-2003, and while stillbirth rates have 
declined due to this, neonatal death rate after a preeclamptic pregnancy has not changed 
significantly (Basso et al., 2006). Taking these observations together, while risk of 
neonatal death post-delivery has not changed in preeclamptic pregnancies, inducing 
pregnancy in preeclamptic patients results in an overall increase in fetal survival.  
 The following is a brief introduction to common mechanical problems of the 
placenta and umbilical cord. Velamentous cord insertion occurs when the umbilical cord 
is inserted into the fetal membranes instead of the body of the placenta. This improper 
insertion leaves the vessels that provide nutrients to the fetus unprotected, making them 
vulnerable to compression and even rupturing (Benirschke et al., 2006). The compression 
of these vessels during development can cause intrauterine growth restriction, and can 
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lead to placental dysfunction and fetal morbidity if it is not carefully monitored 
throughout the pregnancy.  
 Another mechanical cause of placental dysfunction can occur when there is a 
placental infarction. Placental infarctions are thought to occur partly due to poor fetal 
blood flow, or due to the occlusion of maternal spiral arteries during pregnancy, both of 
which will cause a portion of the placental tissue to undergo ischemia induced necrosis 
over time (McDermott & Gillan, 1995). While minor placental infarctions are relatively 
common and tend not to have a negative effect on the fetus, larger, more significant 
placental infarctions can severely limit exchange between the fetus and the mother, 
causing placental dysfunction.   
Developmental Based Etiology of Placental Dysfunction 
 Upon fertilization of a female ovum by a sperm, the newly created zygote 
undergoes multiple cellular divisions as it travels from the fallopian tubes towards the 
uterus. Approximately five to six days after fertilization occurs, the mass of cells is now 
organized into what is known as a blastocyst, and is ready to undergo implantation. Outer 
trophoblast cells lining the blastocyst differentiate into mitotically active 
cytotrophoblasts, which then differentiate into a separate group of trophoblast cells called 
syncytiotrophoblast cells. The syncytiotrophoblast layer is a group of cells that fuse 
together to form a syncytium, which is the primary cellular interface between the 
maternal and fetal circulations (Junqueira & Mescher, 2013). Syncytiotrophoblast cells 
are also responsible for the secretion of human chorionic gonadotropin, a hormone that is 
critical in maintaining the function of the corpus luteum in early pregnancy (Junqueira & 
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Mescher, 2013). During placental invasion of the maternal endometrium and 
myometrium, column-like structures form, lined by syncytiotrophoblasts with 
cytotrophoblasts remaining inside (Chaddha, Viero, Huppertz, & Kingdom, 2004). These 
columns develop from the primary villi into the tertiary villi over the course of the first 
three weeks of gestation, enzymatically breaking down endometrial glands and forming 
lacunae within the syncytiotrophoblasts. 
 Cytotrophoblasts that invade into the endometrium are termed extravillous 
cytotrophoblasts. This group of cells are responsible for two main processes: colonization 
of the decidua, and remodeling the ends of the spiral arteries into a low pressure system 
with highly dilated vessels, creating and enabling a permanent source of maternal blood 
flow. A subset of extravillous trophoblast cells, called endovascular trophoblast cells, 
specialize in occluding the spiral arteries and inevitably prevent maternal blood from 
reaching the intervillous space (Kaufmann, 2003). It is currently thought that this action 
of the endovascular trophoblast cells early in the first trimester of pregnancy induces a 
hypoxic placental environment relative to the mother, which in turn promotes the 
angiogenesis of the tertiary placental villi (Rodesch, Simon, Donner, & Jauniaux, 1992). 
Once angiogenesis has taken place by the end of the first trimester, the endovascular 
trophoblasts no longer block blood flow from the spiral arteries and maternal blood via 
the newly established remodeling begins to oxygenate the placenta at around twelve 
weeks gestation (Burton, Jauniaux, & Watson, 1999). The coordination of these two cell 
types appears to dictate the level of angiogenesis of the placental villi and in turn the size 
of the placenta, which is critical for proper growth of the fetus.  
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 A problem with any step in the process of trophoblast differentiation and 
development can potentially contribute to poor placental development in the first 
trimester of pregnancy, leading to intrauterine growth restriction, preeclampsia, or 
placental dysfunction. Specifically, any aberrations in the differentiation of, or interplay 
between the extravillous cytotrophoblasts and endovascular trophoblasts can potentially 
lead to placental dysfunction as well. While it appears that these two cell types are 
partially responsible for the genesis of complications that can lead to placental 
dysfunction as early as the first trimester, as of now specifics have not been elucidated. 
 There is histologic evidence supporting the premise that preeclampsia, 
intrauterine growth restriction, and placental abruption are manifestations of placental 
dysfunction. In preeclamptic patients, it has been observed that the extravillous 
trophoblasts do not invade past the endometrial-myometrial border as far as in control 
patients, and the endovascular trophoblasts are seen at a much lower density in the 
endometrium of preeclamptic patients when compared to control patients (Kadyrov, 
Schmitz, Black, Kaufmann, & Huppertz, 2003). A related study has also confirmed the 
first observation, reporting a lower percentage of trophoblast cells in the decidua of 
severely hypertensive patients when compared to normotensive patients, while also 
showing a lack of invasion of the myometrial spiral arteries, which are normally 
remodeled and occupied by endovascular trophoblast cells during early pregnancy 
(Naicker, Khedun, Moodley, & Pijnenborg, 2003). One explanation could be due to the 
fact that these trophoblast cells in preeclamptic patients do not express certain cell 
adhesion molecules seen in normal pregnancies during the invasion and remodeling of 
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the uterine spiral arteries, including integrin, cadherin, and Ig superfamily members 
(Zhou, Damsky, & Fisher, 1997). These are thought to be critical for both invasion and 
for the trophoblasts to mimic a vascular phenotype when remodeling the spiral arteries. 
More recent reports have correlated the impaired angiogenesis of placentas in 
preeclamptic patients with elevated serum levels of a soluble vascular endothelial growth 
factor receptor-1, which is thought to competitively inhibit binding of VEGF in the 
placenta and has been shown to inhibit cell migration and tube formation of placental 
villous explants in vitro (Ahmad, 2004).  
Extracellular RNAs as Tools for the Diagnosis of Placental Dysfunction 
 The quest for finding biomarkers that have diagnostic and prognostic value is 
more significant than ever in today's technocentric world. Currently, many of the 
common biomarkers used for diagnostic testing in the clinic include the measurements of 
analytes such as metabolites or proteins in the blood and urine (Etheridge, Lee, Hood, 
Galas, & Wang, 2011). With the advent of new technologies, such as next generation 
sequencing and more sensitive molecular quantification assays, extracellular nucleic 
acids, including deoxyribonucleic acid (DNA) and different classes of ribonucleic acids 
(RNA), now present a new avenue for biomarker discovery. Nucleic acids were first 
detected in serum in 1952 (DeFilippo & Versari, 1952). It wasn't until 1997 that fetal 
DNA was first discovered and extracted from cell free extracts of maternal blood (Y. M. 
Lo et al., 1997). While fetal DNA has been shown to be potentially useful as a prenatal 
diagnostic tool for complications such as fetal aneuploidy, the fact that every cell in a 
given individual contains essentially the same complement of DNA means that the study 
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of circulating DNA lacks the ability to detect the current functional state of the placenta 
and the fetus at a given point in time (Fan, Blumenfeld, Chitkara, Hudgins, & Quake, 
2008). However, since RNAs are more short-lived than DNA and the RNA content of 
cells can vary widely according to cell type and cell status, it is possible that an 
examination of the different types of RNAs present in the maternal circulation may yield 
a snapshot of the current interactions occurring between the mother and the fetus. Since 
the placenta is in constant contact with the maternal blood flow, it follows that shedding 
of placental debris and extracellular vesicles could provide a glimpse into the placental 
transcriptome. By studying the various RNAs in the blood of pregnant women at various 
points in time, different patterns in RNA levels could yield insight to the current state and 
potential complications of the placenta and therefore the fetus throughout pregnancy.  
 The first study demonstrating the presence of endogenous exRNAs in the blood 
was that of tumor-associated RNAs in cell-free plasma samples (K.-W. Lo et al., 1999). 
Within a year of this initial report, the field of maternal fetal medicine converged with the 
new field of exRNAs when fetal RNA was found in the plasma of pregnant women 
carrying male fetuses using probe designed to detect a male specific RNA (Poon, Leung, 
Lau, & Lo, 2000). This study not only provided evidence of exRNAs of fetal origin in the 
maternal circulation, but also opened the door to the idea of fetal signaling to the mother 
through these RNAs. In fact, placental messenger RNAs that code for both hormones and 
transcription factors have been found in maternal plasma, the former of which were found 
at varying levels depending on gestational age (Go et al., 2004; Ng et al., 2003). It is also 
interesting to note that a majority of the fetal RNAs normally detected in the maternal 
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plasma were shown to be cleared within two hours of delivery. Thus, without a placenta 
that is continuously releasing transcripts into the maternal circulation, the signaling 
between the placenta and the mother is rapidly lost due to RNA degradation in the blood. 
This rapid RNA turnover in the maternal blood presents a technical challenge to profiling 
of circulating RNAs in the maternal blood, and it is possible that there are many RNAs in 
the blood that have not been discovered yet. A good candidate biomarker displays a 
unique profile in cases compared to normal controls, and can be reliably measured in all 
subjects; it is possible that instability of circulating RNAs may prevent them from being 
good biomarkers.  
 In 2008, microRNAs were not only observed in human plasma, but were also 
shown to be stable over long periods of time at room temperature, as well as over 
multiple freeze thaw cycles in collected plasma (Mitchell et al., 2008). Their reported 
stability in plasma after collection and the development of sensitive and robust detection 
assays make them good biomarker candidates. microRNAs are short, approximately 22 
nucleotide long non-coding RNAs that possess the ability to regulate gene expression at 
the post-transcriptional level by degrading or destabilizing messenger RNAs (Bartel, 
2004). Upon post-transcriptional processing into their mature form, individual 
microRNAs are loaded into the RNA Induced Silencing Complex, where they can bind to 
and regulate a broad range of target mRNAs in the cytoplasm in a sequence-dependent 
fashion (Selbach et al., 2008). The target specificity of the miRNAs lies largely within 
nucleotides 2-8 on the 5' end of the mature miRNA, which are responsible for the binding 
of miRNAs to their target mRNAs through Watson-Crick base pairing interactions 
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(Lewis, Burge, & Bartel, 2005). These “seed” sequences have been shown to be shared 
among microRNA families, which are groups of miRNAs, sometimes encoded at distant 
sites in the genome, that are coordinately expressed across different tissue types (Laurent 
et al., 2008). In recent years, specific miRNA families have been shown to modulate 
important cell states in development, including the pluripotent stem cell state and the cell 
cycle (Leonardo, Schultheisz, Loring, & Laurent, 2012). microRNAs have been a topic of 
great interest in regard to biomarker discovery and are currently being tested for 
diagnostic potential in many different systems, including different cancer types and drug-
induced liver injury, to name a few (Starkey Lewis et al., 2012; Wittmann & Jäck, 2010).  
 Currently, the methods used to detect elevated risk of placental dysfunction in 
pregnancies include evaluation of maternal risk factors, asking about history of placental 
dysfunction in a previous pregnancy, review of the results of certain analyte levels in the 
maternal blood, evaluation of fetal growth, and interrogation of uterine artery Doppler 
waveforms (“Placental Insufficiency,” 2014). These methods lack both sensitivity and 
specificity, can be costly, and are not available to many pregnant women. Finding an 
effective and inexpensive way to identify pregnancies at risk for placental dysfunction 
that can be applied early in pregnancy would improve the ability of the clinician to 
reassure low-risk patients and to monitor high-risk patients appropriately.  Specifically, if 
a sensitive and specific serum biomarker for elevated risk for placental dysfunction is 
discovered, this test could become a routine test offered to all pregnant women. Since the 
study of extracellular miRNAs in maternal blood is in its infancy, it is not yet known 
whether placental miRNAs can be reliably detected in maternal blood, and whether the 
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miRNA profile changes across gestation.  In this study, we sought to answer these 
fundamental questions. 
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Specific Aims 
 The objective of the present study is to look at the relationship between miRNA 
profiles in placental samples, nonpregnant women and pregnant women at different 
gestational ages. Specifically, we performed: 
1. Collection of serum samples from nonpregnant women, and pregnant women in 
the first and third trimesters of pregnancy (termed “early” and “late” pregnancy 
samples, respectively). Placental tissue samples were from a bank of previously 
collected tissue. 
2. Isolation of total RNA from the collected serum samples followed by 
quantification and quality control assays. 
3. Next generation sequencing library construction using the NEBNext Small RNA 
Library prep kit followed by sequencing using the Illumina HiSeq 2000. Data was 
collected, processed, and normalized for further analysis. 
4. Statistical analysis of the overall data and comparisons between the following 
groups were done: pregnant versus nonpregnant women; early pregnant versus 
late pregnant; and a multi-group comparison between nonpregnant, early pregnant 
and late pregnant groups. 
 These studies were aimed at identifying miRNAs unique to pregnant patients, and 
determining which of them were of likely placental origin. We also sought to discover 
whether there were miRNAs that were unique to early or late pregnancy. We hope these 
studies will shed light on the interactions between the placenta and the mother, and that 
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the techniques we develop will be used in future studies to find biomarkers unique to 
patients at elevated risk of placental dysfunction.
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METHODS 
Patient Samples 
 Serum samples were obtained from nonpregnant and pregnant women presenting 
for pregnancy care at UCSD clinics and hospitals. Approximately 10cc of whole blood 
was collected as a separate venipuncture or during a routine clinical blood draw into 
sterile red top vacutainer tubes (BD). The tubes were then inverted 5-10 times and then 
placed upright for 10 minutes to allow for clotting to occur. Samples were processed 
within two hours of the initial blood collection. Once clot formation occurred, tubes were 
centrifuged at 1200xg for 10 minutes and then the serum was pipetted in 500 uL aliquots 
into labeled 2.0 mL sterile conical screw cap tubes (Fisherbrand). Samples were then 
placed immediately into a secure -80o C freezer for storage. 
RNA Isolation from Placental Tissue 
 Approximately 100mg of placental tissue was first homogenized in lysis buffer 
using a Mini-Beadbeater-24 (Biospec) for one minute. The homogenate was then 
collected into a new 1.5mL microfuge tube and further processed using the mirVana 
miRNA Isolation Kit (Ambion) according to manufacturer’s instructions and eluted in 
50uL of nuclease free water. RNA was quantified using the Qubit RNA Broad Range 
Assay (Life Technologies), and quality was assessed using the RNA 6000 Nano Kit 
(Agilent).  
RNA Isolation from Serum 
 Total RNA was isolated from 500uL serum samples from five nonpregnant, four 
first trimester and four third trimester females. First, serum samples were homogenized 
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by adding TRIzol LS Reagent (Ambion) at a 3:1 ratio of TRIzol to sample volume, 
followed by vortexing. Chloroform was then added in a ratio of 0.2mL per 0.75mL 
TRIzol and samples were mixed by vigorously shaking for 15 seconds. Samples were 
incubated at room temperature for five minutes and then centrifuged at 12,000xg for 15 
minutes at 4o C. The resulting aqueous phase was collected and further processed using 
the column-based purification with the miRNeasy kit (Qiagen). Samples were eluted in 
30uL of water and concentrated using a SpeedVac (Thermo Scientific) until there were 
approximately 10uL left.  Two microliters of each eluted sample were used to quantify 
both the concentration total RNA using the Quant-iT RiboGreen RNA Reagent and Kit 
(Life Technologies) on the Infinite M200 Pro microplate reader (Tecan), and the sample 
quality using the RNA 6000 Pico Kit (Agilent) on the 2100 Bioanalyzer (Agilent).  
cDNA Library Preparation and Sequencing 
 Complementary DNA (cDNA) libraries were prepared using the NEBNext Small 
RNA Kit according to manufacturer’s instructions (NEB). Briefly, Isolated RNA from 
serum (up to 6uL) or 50 nanograms of placental RNA was ligated to the 3’ adaptor for 
one hour. Following ligation, a reverse transcription primer was hybridized to bind to all 
excess 3’ adaptors in solution to prevent adaptor-dimer formation. RNA was then ligated 
to the 5’ adaptor for one hour followed by reverse transcription. Once the RNA was 
reverse transcribed into cDNA, a PCR amplification step was done for 15 cycles. 
Amplified cDNA was then purified by size selection using AMPure XP Beads according 
to manufacturer’s instructions and eluted in a final volume of 15uL of nuclease free 
water. Two microliters of each eluted sample were used to quantify both the 
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concentration of the cDNA libraries using the Quant-iT High Sensitivity DNA Kit (Life 
Technologies) on the Infinite M200 Pro microplate reader (Tecan), and the sample 
quality using the High Sensitivity DNA Kit (Agilent) on the 2100 Bioanalyzer (Agilent). 
Indexed cDNA libraries were then pooled to yield a final concentration of two 
nanomolar. Samples were submitted to the UCSD Genomics Core and run on the 
Illumina HiSeq 2000 using 100 base pair, paired end reads according to manufacturer’s 
instructions (Illumina).  
Data Analyses 
 Demultiplexed fastq files were assessed for quality using FastQC (“FastQC,” 
2014). The reads were first trimmed using the FASTX-Toolkit (“FASTX-Toolkit,” 2014) 
to 26 base pairs. The reads were additionally trimmed using Trim Galore (“Trim Galore,” 
2014) to remove reads with bases whose quality scores were below 20 and read lengths 
below 18 base pairs. The reads were then collapsed into a read-count format, which lists 
the sequence followed by the number of times the sequence appeared in the trimmed 
fastq file, using a custom in-house perl script. The read-counts were then mapped to the 
reference genome assembly version hg19 (“UCSC Genome Bioinformatics,” 2014) using 
miRanalyzer with default parameters (Hackenberg, Rodriguez-Ezpeleta, & Aransay, 
2011). Analysis of the mapped reads was performed in Qlucore Omics Explorer 3.0 
(“Qlucore,” 2014).   
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RESULTS 
  
Sample Statistics  
 Next generation sequencing was conducted on serum samples from five 
nonpregnant, four first trimester pregnant, and four third trimester pregnant patients, 
along with four placental tissue samples for a total of 17 samples. An average of 2.6 
million total reads per serum sample was recorded, with an average of 5.5 million total 
reads for the placental tissue samples. Approximately 9% of total reads were successfully 
mapped to known miRNAs in the serum samples, with 12% of total reads from placental 
samples mapped to miRNAs (Table 2). In a separate analysis, a subset of the sequenced 
data was used to analyze the distribution of mapped reads among all small RNA types 
(Figure 1). Interestingly, the percentage of miRNAs, long noncoding intergenic RNAs 
(lincRNA) and coding sequences (cds) remained the same between groups, with miRNA 
averaging close to 17% of the total mapped reads between all sample groups.  
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Figure 1: small RNA Profiles of Nonpregnant, Pregnant and Placental Samples. The 
mapped data for a subset of the sequenced samples was taken to analyze the distribution 
of RNAs within each group. Each pie graph represents 100% of the total mapped reads 
for that group, with the percentage of mapped reads to each RNA type labeled above. 
Table 2. Sequencing Read Alignment. Table showing the total number of reads, the 
number of mapped reads to microRNAs, and percentage of total reads that aligned to 
miRNAs using the reference genome hg19 for each sample.  
SAMPLE NAME 
Total 
Reads 
Total 
Aligned 
Reads to 
miRNA 
 
Number 
Aligned 
1 Time 
Number 
Aligned 
>1 time 
Percentage 
Aligned to 
miRNA 
Early Pregnant 1 816397 76758 60917 15841 0.09 
Early Pregnant 2 1097392 85000 67571 17429 0.08 
Early Pregnant 3 1557317 167434 125838 41596 0.11 
Early Pregnant 4 1339243 163727 116871 46856 0.12 
Late Pregnant 1 7750064 518940 421735 97205 0.07 
Late Pregnant 2 6170142 447235 350387 96848 0.07 
Late Pregnant 3 4310104 283286 229082 54204 0.07 
Late Pregnant 4 2864431 121794 97176 24618 0.04 
Nonpregnant 1 1942056 83017 62917 20100 0.04 
Nonpregnant 2 1082580 177215 133855 43360 0.16 
Nonpregnant 3 1432575 223367 163182 60185 0.16 
Nonpregnant 4 1674969 119514 94642 24872 0.07 
Nonpregnant 5 1360045 123767 103876 19891 0.09 
Placenta 1 4770745 665106 522079 143027 0.14 
Placenta 2 5441531 621898 466396 155502 0.11 
Placenta 3 9592219 1531531 1171372 360159 0.16 
Placenta 4 2083500 162696 140066 22630 0.08 
            
Average 
Placental 5471999 745308 574978 170330 0.12 
Average Serum 2569024 199312 156004 43308 0.09 
Total  55285310 5572285 4327962 1244323   
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Early and Late Pregnancy Samples Differ in miRNA Profiles  
 In order to detect potential differences in miRNA expression profiles between 
different gestational ages, a two-tailed t-test with a level of significance of 5% was 
conducted between the early pregnancy (EP) and late pregnancy (LP) subgroups (Figure 
2). Of the 1391 starting miRNAs, 94 were identified as statistically significant (Figure 2). 
First, the data for the EP and LP samples only were visualized, and revealed that 
miRNAs from two large clusters on Chr 14 and Chr 19 were expressed at significantly 
higher levels in LP samples (Figure 3A). Subsequently, the data for these 94 selected 
miRNAs was shown for all 17 samples to examine their expression levels in the placental 
and nonpregnant (NP) samples (Figure 3B).   
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Figure 2: Early vs. Late Pregnancy Comparison. Venn diagram showing the 
experimental setup comparing late and early pregnancy samples. miRNAs, which were 
either more highly expressed in the early pregnancy group when compared to the late 
pregnancy group or vice versa were found performing one two-tailed t-test.  
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Figure 3: Chromosomal Distribution of Early vs. Late Pregnancy miRNAs. Heat 
maps displaying the 94 miRNAs differentially expressed between early and late 
pregnancy, with unbiased hierarchical clustering of the samples. miRNAs are arranged 
based on chromosome number followed by chromosomal location.  A) Data for EP and 
LP samples only. B) Data for placental, EP, LP, and NP samples. Data was log 
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transformed. Expression level legend is to the right, with high expression in yellow and 
low expression in blue.   
Pregnancy Specific miRNAs 
Early and late pregnancy samples were each compared to the nonpregnant samples by 
conducting one-way t-tests with a p-value cutoff of <0.05, thus revealing miRNAs that 
were more highly expressed in either EP or LP compared to NP (Figure 4). This resulted 
in 46 of the 1391 miRNAs showing significantly higher expression in EP when compared 
to NP, while 152 of the 1391 miRNAs showed higher expression in LP compared to NP 
(data not shown). A subset of 20 miRNAs was significantly expressed at higher levels in 
both EP and LP compared to NP, distinguishing them as pregnancy-specific miRNAs 
(Figure 5). A total of 196 of the 1391 miRNAs were found to be more highly expressed 
in either EP, LP, or both compared to NP. This set of miRNAs was enriched in miRNAs 
located on chromosomes 14 and 19, with 66 of the 196 miRNAs located on one of the 
two chromosomes, as can been seen in Figure 6.   
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Figure 4: Pregnant vs. Nonpregnant Comparison. Venn diagram showing the 
comparisons between each gestational age group and the nonpregnant group. Intersect is 
the number of miRNAs that were overexpressed in both groups. All miRNAs that were 
either highly expressed in LP or EP when compared to NP individually and were kept for 
further analysis.  
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 Figure 5: Pregnancy Specific microRNAs. Expression of microRNAs that were highly 
expressed in both pregnancy groups when compared to nonpregnant groups is shown in 
the heatmap above. miRNAs are arranged by chromosome number followed by 
chromosomal location, with samples grouped by unbiased hierarchical clustering. 
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Figure 6: Chr14 and Chr19 Expression in Pregnancy. Chromosomal expression of 
miRNAs that were found upregulated in EP, LP, or both compared to NP. miRNAs are 
arranged by chromosome number followed by chromosomal location, with samples 
grouped by unbiased hierarchical clustering. Data was log transformed. 
microRNAs Unique to Nonpregnant, Early Pregnancy, and Late Pregnancy 
Three independent one-tailed t-tests with a p-value cutoff of <0.05 were performed 
between EP and LP, EP and NP, and NP and LP. miRNAs that showed significantly 
higher in expression in each group compared to both of the other groups were considered 
specific to that group. This comparison yielded a total of 74 microRNAs, with two unique 
to NP, four unique to EP, and 68 unique to LP (Figure 7). The data for these miRNA 
probes for all four sample types were displayed after a log transformation to look for any 
correlation to placental expression (Figure 8). This data was then plotted on a principal 
component analysis plot in order to compare the relationship of placental expression of 
these miRNAs to their expression in the EP, LP, and NP groups (Figure 8).     
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Figure 7: Early, Late and Nonpregnant Comparison. Venn diagrams show the 
comparisons between each group. miRNAs that were uniquely more highly expressed in 
one group when compared to the other two were considered unique to that group and are 
shown as the intersects of each Venn diagram. 
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Figure 8: Expression Profiles of Group-Specific miRNAs. A miRNA expression 
profile of all samples for the microRNAs unique to each sample group. These groups are 
separated by white spaces and are coded on the right of the figure. The data was log 
transformed, followed by unbiased hierarchical clustering of the samples with the 
miRNAs in chromosomal order followed by chromosome location.  
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Figure 9: PCA Plot of Group Specific miRNAs. The following is a principal 
component analysis plot showing the relationship of every sample within each group 
based on 3-dimensional spatial arrangement. miRNAs uniquely expressed in either early 
pregnant, late pregnant, or nonpregnant groups were used in this analysis. 
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DISCUSSION 
 
 Rigorous profiling of exRNAs in maternal serum has the potential to yield 
diagnostic and prognostic biomarkers for a variety of pregnancy complications as well as 
to identify miRNAs that may mediate fetal-maternal communication. It has become 
apparent that cells of the placenta release miRNAs into the circulation via apoptotic 
placental shedding, packaging these miRNAs into exosomes or microvesicles before 
releasing them, or transporting them into the maternal circulation by some other unknown 
mechanism (Ouyang, Mouillet, Coyne, & Sadovsky, 2014). Our results indicate not only 
that miRNA of placental origin are specifically found in the serum of pregnant women, 
but that the abundance of these placental miRNAs varies across gestational age. 
Examining the early and late gestation serum miRNA profiles in the context of published 
data on trophoblast miRNA expression reveals that the differences in the serum miRNA 
profiles reflects changes in placental miRNA expression with gestational age (Morales-
Prieto et al., 2012). Examining the overall relationships among the four groups of 
samples in our study (placenta, nonpregnant, early pregnant, and late pregnant), it is clear 
that the late pregnant profile resembles the placental profile, while the early pregnant 
profile resembles the nonpregnant profile more closely (Figure 3).  
 In particular, a large group of Chromosome 14 miRNAs was identified as 
specifically expressed in the late pregnant group compared to the nonpregnant and early 
pregnant groups (Figure 6). The Chromosome 19 miRNA cluster was expressed in both 
the early and late pregnant groups, but more highly in the late pregnant group (Figure 6). 
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One possible reason for the similarity between the late pregnant and placenta profiles is 
the growth of the placenta. The placenta has been shown to grow linearly throughout 
pregnancy, with RNA levels increasing linearly with placental weight until the pregnancy 
reaches term (Winick, Coscia, & Noble, 1967). Due to the increasing size and ability to 
produce larger quantities of RNA over time, the placenta could be producing much more 
significant amounts of miRNA to be released than the smaller placenta in the first 
trimester, inevitably having a larger influence on the miRNA expression profile in the 
maternal circulation.  
 In a recent report, blood samples from pregnant patients were sequenced and 
compared to nonpregnant blood samples, in the hopes of finding a placental microRNA 
signature. This paper identified members of the miR-498 cluster as highly abundant in 
placental tissue and maternal and fetal plasma (Williams et al., 2013). Our data correlated 
with this finding, and out of the 20 miRNAs determined to be "pregnancy specific" (i.e. 
expressed at significantly higher levels in both early and late pregnant compared to 
nonpregnant), all of the miRNAs from chromosome 19 fell within the miR-498 cluster 
(Figure 5). This not only demonstrates reproducibility within the sequencing of 
extracellular RNAs between independent lab groups, but also shows a consistent group of 
miRNAs that are highly expressed in pregnant samples.  
 In an analysis to identify microRNAs specific to either the early pregnant, late 
pregnant, or nonpregnant groups, the EP and NP groups clustered quite closely together 
(Figure 9), while the LP group was clearly distinct. This is consistent with the finding 
that the late pregnancy group had a much more significant miRNA signature when 
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compared to the others, with 68/74 of the "group-specific" miRNAs falling within the LP 
group (Figure 8). Only 6/74 probes identified were specific to either the EP group or NP 
group, leading to weak nonpregnant and early pregnant microRNA signatures. This result 
could be due to the lack of a large sample size or the lack of depth of sequencing for each 
individual sample.  
 In this study, we developed an effective method to obtain high quality small RNA 
sequencing data from the exRNA of serum samples and also total RNA from placental 
tissue samples. Our efforts to explore the miRNA profiles across pregnant samples of 
different gestational ages and nonpregnant samples confirmed observations that have 
been previously seen in the field, including a pregnancy-specific microRNA signature. 
We also identified two chromosomes as being enriched in pregnancy related microRNAs, 
chromosomes 14 and 19. A novel finding of this study is the dramatic difference between 
the exRNA signatures of serum samples from early and late pregnancy, highlighting the 
need for gestational age-matched controls for our future studies aimed at identifying 
miRNA signatures indicative of pregnancy complications.  
 In future studies, we will also examine other RNA types in maternal serum. This 
can be done using RNA isolation kits that capture total RNA, rather than enriching for 
small RNAs. An interesting approach in finding biomarkers for placental dysfunction 
would be to utilize both small RNA sequencing and total RNA library preparation kits to 
gain a more comprehensive picture of the exRNAs that vary across gestation age and 
between normal and affected pregnancies. Overall, our results provide a promising start 
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to the analysis of exRNA levels in the maternal circulation, and will be used as a 
backbone for subsequent studies to come.   
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